Genotype 1 Chronic Hepatitis C With Combination Therapy Therapeutics
1. Victrelis patent expiration
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease; Treatment of chro...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(1 year, 17 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(1 year, 10 months from now) | |
| US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Dosage: CAPSULE
More Information on Dosage
VICTRELIS family patents
